Citation, DOI, disclosures and article data
At the time the article was created Matt A. Morgan had no recorded disclosures.View Matt A. Morgan's current disclosures
Gadoversetamide (also known as OptiMARK) is an extracellular intravenous contrast agent used in magnetic resonance imaging.
linear, non-ionic molecule
100% renally excreted
T1 relaxivity at 1.5 T: 4.4-5.0
concentration: 0.5 mmol/mL
recommended dosage: 0.1 mmol/kg
As an extracellular contrast agent, gadoversetamide can be useful in a wide range of MRI applications, including (but not limited to): hepatic imaging, pelvic imaging, cardiac imaging, brain and spine imaging, and musculoskeletal imaging.
There is an association between the use of gadolinium-based contrast agents (GBCAs) in patients with kidney dysfunction and nephrogenic systemic fibrosis (NSF), a rare, but serious, condition. As a result, the use of three GBCAs; gadoversetamide (OptiMARK), gadopentetate dimeglumine (Magnevist) and gadodiamide (Omniscan) are contraindicated in patients with acute kidney injury or with chronic, severe kidney disease 2.
- 1. Guglielmo F, Mitchell D, Gupta S. Gadolinium Contrast Agent Selection and Optimal Use for Body MR Imaging. Radiol Clin North Am. 2014;52(4):637-56. doi:10.1016/j.rcl.2014.02.004 - Pubmed
- 2. FDA. Information for healthcare professionals: Gadolinium-based contrast agents for magnetic resonance imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance). link: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-warnings-using-gadolinium-based-contrast-agents-patients-kidney